CoChat

Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors

Open access
Lim, Ah Reum, Kim, Boyeon, Kim, Jwa Hoon, Hyun, Myung Han, Park, Kyong Hwa, Kim, Yeul Hong, Lee, Soohyeon · 2024 · Frontiers in Oncology

The DOI matches its Crossref record; 42 of the 54 references it cites were found in a registry or an index.

Abstract

Background: This phase Ib study was performed to determine the safety of combination capecitabine with alpleisib (phosphatidylinositol 3-kinase catalytic subunit p110α blockade) and determine the maximal tolerated dose (MTD) and recommended phase ll dose (RP2D) of this combination regimen in patients with advanced solid tumors refractory to standard therapy. The synergistic anti-tumor activity and pharmacokinetics (PK) were investigated. Methods: Dose escalation phases were conducted in patients with advanced solid cancers who were refractory to standard therapy regardless of PIK3CA mutation. Patients were administered orally once daily alpelisib (200mg and 300mg) and twice daily capecitabine (850mg, 1000mg, 1250mg orally, days 1–14) every 3 weeks. Standard “3 + 3” dose escalation was used to define the MTD. The effect of alpelisib on the PK of capecitabine was assessed. Results: Patients with 6 colorectal cancer (three PIK3CA mutation) and 6 breast cancer (all PIK3CA mutation) were enrolled. The first three patients in dose level 0 (alpelisib 200mg daily, capecitabine 1,000 mg/m 2 twice daily) had no dose-limiting toxicities (DLTs). In dose level 1 (alpelisib increased to 300 mg daily, capecitabine 1,000mg twice daily), one of six patients had DLT (grade (Gr) 3 hyperglycemia). When dose level 2 (alpelisib 300mg daily, capecitabine 1,250 mg/m 2 twice daily) was expanded to 3 patients, no patients had DLTs. The combination of alpelisib 300mg daily and capecitabine 1,250 mg/m 2 twice daily was declared as the MTD/RP2D in patients with advanced solid tumors. The most common AEs were Gr 1–3 hyperglycemia (75.0%). Frequent all-grade, treatment-related AEs included Gr 2–3 nausea (75.0%), Gr 1–2 diarrhea (50.0%), Gr 1–2 hand-foot syndrome (41.7%), Gr 1–2 anorexia (41.7%), Gr 2 mucositis (33.3%). Antitumor activity was observed in patients with PIK3CA mutant breast cancer (3 partial response and 3 stable disease of total 6 patients). Alpelisib exposure (C max and AUC 0-12) was unaffected by concomitant capecitabine. There were no clinically relevant drug-drug interactions observed between alpelisib and capecitabine. Conclusions: The combination of alpelisib and capecitabine is generally tolerated, without pharmacokinetic interactions, and shows antitumor activity in patients with PIK3CA mutant advanced cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2024.1390452

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Swimmer’s plot of patients undergoing capecitabine and alpelisib (n=12). Each individual progression free survival (PFS) is plotted from time of first dose (x-axis). Arrows indicate that no disease progression was found during the study period.
Figure 1 Swimmer’s plot of patients undergoing capecitabine and alpelisib (n=12). Each individual progression free survival (PFS) is plotted from time of first dose (x-axis). Arrows indicate that no disease progression was found during the study period.CC BY · PubMed Central
Figure 2 Plasma concentrations (mean ± standard error) of (A) alpelisib, and (B) capecitabine versus time.
Figure 2 Plasma concentrations (mean ± standard error) of (A) alpelisib, and (B) capecitabine versus time.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 12

Metadata

Authors
Lim, A. R., Kim, B., Kim, J. H., Hyun, M. H., Park, K. H., Kim, Y. H., & Lee, S.
Affiliations
  • Korea University Anam Hospital (KR)
  • Korea University (KR)
Venue
Frontiers in Oncology
Published
2024-07-12
Volume
14
Pages
1390452-1390452
ISSN
2234-943X (ISSN-L)
OpenAlex
W4400594726
Cited by
10
References
54
Citations by year
2026: 1 · 2025: 8 · 2024: 1
FWCI
1.36
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Korea Health Industry Development Institute (HI17C2206)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
alpelisib, capecitabine, PIK3CA inhibitors, advanced solid tumors, combination chemotherapy, maximum tolerated dose, recommended phase 2 dose, pharmacokinetics, drug-drug interactions, colorectal cancer, breast cancer, hyperglycemia, dose-limiting toxicity, refractory cancer, oral anticancer drugs, hand-foot syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors. https://app.cochat.ai/papers/10.3389/fonc.2024.1390452
The paper
Lim, A. R., Kim, B., Kim, J. H., Hyun, M. H., Park, K. H., Kim, Y. H., & Lee, S. (2024). Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors. Frontiers in Oncology. https://doi.org/10.3389/fonc.2024.1390452

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.